AbbVie, I-Mab partner on cancer mAb, I-Mab raises $418M

By The Science Advisory Board staff writers

September 4, 2020 -- AbbVie and I-Mab have signed a global collaboration agreement for the development and commercialization of lemzoparlimab (TJC4), an anti-CD47 monoclonal antibody (mAb).

Lemzoparlimab was discovered and developed by I-Mab for the treatment of multiple cancers. It is designed to minimize inherent binding to normal red blood cells while preserving strong anti-tumor activity. Phase I clinical results suggest that the drug is safe and well-tolerated.

The collaboration provides AbbVie with an exclusive global license, excluding China, to develop and commercialize lemzoparlimab. Both companies will collaborate to design and conduct further global clinical trials to evaluate the product in multiple cancers.

I-Mab will retain all rights to develop and commercialize the product in mainland China, Macau, and Hong Kong. The partnership allows for the potential to collaborate on future CD47-related therapies. The companies will share manufacturing responsibilities with AbbVie being the primary manufacturer for global supply.

Under the terms of the agreement, AbbVie will pay I-Mab $180 million in an upfront payment along with $20 million in a milestone payment based on phase I results, for a total of $200 million. I-Mab will also be eligible to receive up to $1.74 billion in success-based milestone payments. Upon commercialization, AbbVie will also pay tiered royalties on global net sales outside of greater China.

In other news, I-Mab announced that the company raised approximately $418 million through a private placement led by Hillhouse Capital Group. The company intends to use the funds to pay for ongoing and planned research and clinical programs globally as well as the development of commercialization capabilities in China.

Will a COVID-19 vaccine enable us to return to normal? | Cancer research embraces NGS
Will a COVID-19 vaccine enable us to return to normal? | Cancer research embraces NGS
AbbVie, Harvard partner on $30M emerging virus research
AbbVie and Harvard University announced a $30 million collaborative research alliance to study therapies against emerging viral infections.
Alpine and AbbVie to develop, commercialize immunotherapy
Alpine Immune Sciences and AbbVie have entered an exclusive worldwide option and license agreement for ALPN-101, a dual cluster of differentiation 28...
AbbVie licenses antibody technology for COVID-19
AbbVie, Harbour BioMed, Utrecht University, and Erasmus Medical Center announced that they have entered into a collaboration to develop a novel antibody...
AbbVie, Jacobio to collaborate on SHP2 inhibitors
AbbVie and Jacobio Pharmaceuticals announced they are partnering to develop and market SHP2 inhibitors, which target a node in cancer and immune cells.

Copyright © 2020

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter